Compare Mesoblast Limited (MESO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Mesoblast Limited trades at $17.03 (market cap $2.21B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.37. The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MESO | TLT | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $92.06 |
52-Week Low | $12.88 | $82.05 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.40, up 0.43% on the day, amid a bearish technical signal with selling pressure dominating moving averages. Recent news highlights rising Treasury yields and inflation concerns, with institutional buying noted. The ETF provides exposure to long-term U.S. government bonds, with dividend distributions continuing regularly.
Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income but facing headwinds from potential Fed policy shifts. Key risks include yield volatility and macroeconomic factors impacting bond prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
